Ehsan Keshavarzian, Tella Sadighpour, Seyed Mohammadreza Mortazavizadeh, Mohammadhossein Soltani, Amir Farzin Motevalipoor, Shahriyar Shahbazi Khamas, Mohammad Moazen, Mohamad Kogani, Seyed Mohammad Amin Hashemipour, Hamid Hosseinpour, Rohollah Valizadeh
BACKGROUND: Anthracyclines can improve survival in many types of malignancies, but dose-dependent and irreversible results following the use of anthracyclines have been associated with cardiomyopathy. This meta-analysis aimed to compare the effects of prophylactic agents for preventing cardiotoxicity induced following anticancer agents. METHODS: In this meta-analysis, Scopus, Web of Science, and PubMed were surfed for articles published by December 30th, 2020. The keywords were angiotensin-converting enzyme inhibitor (ACEI), enalapril, captopril, angiotensin receptor blocker, beta blocker, metoprolol, bisoprolol, isoprolol, statin, valsartan, losartan, eplerenone, idarubicin, nebivolol, dihydromyricetin, ampelopsin, spironolactone, dexrazoxane, antioxidants, cardiotoxicity, n-acetyl-tryptamine, cancer, neoplasms, chemotherapy, anthracyclines, doxorubicin, daunorubicin, epirubicin, idarubicin, ejection fraction or a combination of them in the titles or abstracts...
February 17, 2023: Reviews on Recent Clinical Trials